ImmunityBio (IBRX) AI Stock Analysis

• Market Cap: $2.41B
• Dividend Yield: N/A
• Average Volume (3M): 6.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.42
• Revenue Growth: 2270.58%
• EPS Growth: 46.82%
• Country: US
• Employees: 628
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.63
• Shares Outstanding: 853,442,140
• 10 Day Avg. Volume: 6,461,679
• 30 Day Avg. Volume: 6,089,140
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 168.43
• Price to Cash Flow (P/CF): -7.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.08
• Price Target Upside: 111.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

ImmunityBio's overall stock score is low due to significant financial instability, including persistent losses, high leverage, and negative cash flows. While there is some revenue growth, the company remains unprofitable, and its valuation is unattractive with a negative P/E ratio. Technical analysis indicates potential for a short-term reversal, but the overall trend is bearish.

Positive Factors

Market Expansion

ImmunityBio is expanding its market penetration by filing a BLA for BCG-unresponsive papillary NMIBC (70–80% of NMIBC cases) in 2025, with Phase 2 data in the BCG-naïve setting potentially yielding top-line results by late 2025/2026.

Strategic Collaborations

The exclusive global arrangement with the Serum Institute of India for the supply of BCG provides a key strategic advantage to IBRX given the current BCG shortage.

Negative Factors

Product Adoption Challenges

Supply of recombinant BCG is ready for shipment and is expected to increase BCG supply for physicians, addressing key hurdles for ANKTIVA's adoption.

ImmunityBio Business Overview & Revenue Model

Company Description

NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.

How the Company Makes Money

ImmunityBio makes money primarily through the development and commercialization of immunotherapy products, which involve generating revenue from product sales, licensing agreements, and collaborations with other pharmaceutical companies. The company engages in partnerships to co-develop and co-market its therapeutic candidates, which can provide upfront payments, milestone payments, and royalties. Additionally, ImmunityBio may receive funding and grants from governmental or non-governmental organizations to support its research and development efforts, contributing to its revenue streams.

ImmunityBio Financial Statement Overview

Summary

ImmunityBio is facing significant financial challenges, with persistent losses, high leverage, and negative cash flows. While there is some revenue growth, the company remains heavily reliant on external financing to sustain operations. The negative equity and cash flow deficits highlight the need for improved operational efficiency and financial management to ensure long-term viability.

Income Statement

ImmunityBio has shown some revenue growth in the latest year, with revenue increasing from $622,000 to $14.7 million. However, the company has been consistently unprofitable, with negative net profit margins and EBIT margins over the years. The gross profit margin remains positive, but the high levels of operating losses and negative EBITDA indicate significant profitability challenges.

Balance Sheet

The company's balance sheet shows high leverage, with total liabilities exceeding total assets, resulting in negative stockholders' equity. This poses a risk for financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, and the negative return on equity further highlights profitability issues.

Cash Flow

ImmunityBio's cash flow statement reflects substantial operating cash flow deficits, which have worsened over the years. The free cash flow remains negative, indicating ongoing challenges in generating cash from operations. Although the company has raised financing in previous years, the consistent negative free cash flow poses a risk to sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
14.74M	622.00K	240.00K	934.00K	605.00K
	Gross Profit
14.74M	622.00K	-23.95M	934.00K	-8.54M
	EBIT
-344.18M	-362.25M	-351.30M	-330.28M	-220.88M
	EBITDA
-264.43M	-436.18M	-335.51M	-315.38M	-187.93M
	Net Income Common Stockholders
-413.56M	-583.20M	-417.32M	-349.85M	-224.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
149.81M	266.46M	107.18M	317.12M	96.06M
	Total Assets
382.93M	504.45M	362.36M	468.91M	221.38M
	Total Debt
42.29M	726.72M	723.77M	645.66M	275.55M
	Net Debt
-101.14M	461.27M	619.13M	464.56M	240.63M
	Total Liabilities
871.06M	1.09B	812.18M	712.82M	339.87M
	Stockholders Equity
-488.13M	-586.99M	-447.33M	-242.17M	-119.81M
Cash Flow		Free Cash Flow
-398.12M	-397.34M	-436.90M	-307.98M	-173.39M
	Operating Cash Flow
-391.24M	-366.76M	-337.51M	-274.42M	-171.72M
	Investing Cash Flow
-12.25M	-30.47M	27.30M	-84.89M	-19.81M
	Financing Cash Flow
281.63M	558.34M	233.61M	505.44M	150.68M

ImmunityBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Negative. The current price of 2.87 is below the 20-day moving average (MA) of 3.17, below the 50-day MA of 3.05, and below the 200-day MA of 4.33, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 44.02 is Neutral, neither overbought nor oversold. The STOCH value of 20.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IBRX.

ImmunityBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	50 Neutral	$95.46M	―	-101.50%	―	76.24%	38.67%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
ADAP	44 Neutral	$114.38M	―	-53.54%	―	145.37%	57.01%
BLUE	42 Neutral	$38.57M	―	-270.20%	―	144.50%	-141.91%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%
IBRX	39 Underperform	$2.41B	―	78.99%	―	2270.58%	46.82%

ImmunityBio Corporate Events

ImmunityBio Approves 2024 Executive Bonuses and New Incentives

On February 7, 2025, ImmunityBio’s Compensation Committee approved 2024 executive bonuses for its key officers, reflecting an 80% payout of the target amount, with payments scheduled for March 14, 2025. Additionally, the company announced its 2025 Long-Term Incentive Program, granting stock options and restricted stock units to executives, with awards set to vest over three years, and set new base salary rates effective March 10, 2025.